UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2012

Commission File Number: 001-34564

China Nuokang Bio-Pharmaceutical Inc.

No. 18-1 East Nanping Road

Hunnan National New & High-tech Development Zone

Shenyang, Liaoning Province

People’s Republic of China 110171

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


China Nuokang Bio-Pharmaceutical Inc.

By:		/s/ Baizhong Xue
Name:		Baizhong Xue
Title:		Chairman and Chief Executive Officer

Date: September 28, 2012

Exhibit Index


Exhibit No.		Description

Exhibit 99.1		Press Release

Exhibit 99.2		Agreement and Plan of Merger by and among Kingbird Investment Inc., Kingbird Mergerco. Inc., China Nuokang Bio-Pharmaceutical Inc. and certain other parties thereto dated as of September 27, 2012

China Nuokang Bio-Pharmaceutical Inc. 6-K